Jubilant Pharma develops a novel oral formulation of Remdesivir.
Jubilant Pharma on Monday announced that it has developed a novel oral formulation of Remdesivir, which, the company said, is likely to ease the capacity constraint that injectable formulation faces and ensure wider and timely availability for covid-19 patients. The development includes successful completion of safety and studies showing absorption of the oral formulation in bodies of animals and healthy human volunteers in India, the company said. Jubilant Pharma has sought authorisation for additional studies for the oral formulation from the Drug Controller General of India (DCGI)…